<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01758406</url>
  </required_header>
  <id_info>
    <org_study_id>Royan-Heart-003</org_study_id>
    <nct_id>NCT01758406</nct_id>
  </id_info>
  <brief_title>Transplantation of Autologous Cardiac Stem Cells in Ischemic Heart Failure</brief_title>
  <official_title>Therapeutic Outcome of Intracoronary Transplantation of Autologous Cardiac Stem Cells in Patients With Ischemic Heart Failure: Randomized Double Blind Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Royan Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Royan Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a prospective, randomized, double blind , controlled trial to assess the
      efficacy of intracoronary transplantation of autologous cardiac stem cells in 50 patients
      with ischemic heart failure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Heart failure is a common, costly, disabling, and potentially deadly condition. Heart
      transplantation is the ultimate approach to treating heart failure, but this is costly and
      excludes patients who are poor candidates for transplantation given their co morbidities, or
      for whom a donor organ is unavailable. Currently, there is no effective intervention to
      regenerate dead heart muscle after a heart attack. Our hypothesis is that CSCs regenerates
      myocardium. In this study all eligible patients are randomly allocated into two study groups
      by a permuted block randomization method: group A (case group) received 5-10 millions
      autologous cardiac stem cells, group B (control group) just received placebo. They follow up
      for 18 months.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">November 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>death</measure>
    <time_frame>18months</time_frame>
    <description>evaluation the rate of patients mortality after cardiac stem cell transplantation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>arrhythmia</measure>
    <time_frame>18months</time_frame>
    <description>Evaluation rate of arrhythmia after cardiac stem cell transplantation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>hospitalization</measure>
    <time_frame>18 months</time_frame>
    <description>Evaluation the rate of hospitalization after cardiac stem cell transplantation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ejectin fraction changes</measure>
    <time_frame>18months</time_frame>
    <description>evaluation the elevation of ejection fraction in patients after cardiac stem cell transplantation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pro BNP changes</measure>
    <time_frame>18months</time_frame>
    <description>Evaluation the reduction of Pro BNP in patients after cardiac stem cell transplantation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NYHA functional class</measure>
    <time_frame>18months</time_frame>
    <description>Evaluation the improvement of NYHA functional class in patients after cardiac stem cell transplantation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6MW test</measure>
    <time_frame>18months</time_frame>
    <description>Evaluation the improvement of 6MW test after cardiac stem cell transplantation.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>cardiac stem cell transplantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients with heart failure that underwent cardiac stem cell transplantation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The patients with heart failure that underwent placebo injection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Intracoronary injection</intervention_name>
    <description>stem cell transplantation</description>
    <arm_group_label>cardiac stem cell transplantation</arm_group_label>
    <other_name>autologous cardiac stem cell intracoronary injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Intracoronary injection of Placebo</intervention_name>
    <description>Injection of Placebo via coronary arteries in patients with heart failure.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1- EF≤40 (by Echocardiography) 2- Not responding to standard therapies for heart
             failure &gt;1m 3- NYHA class ≥ III 4- Myocardial infarction due to coronary artery
             atherosclerotic disease 5-An area of regional dysfunction, i.e., hypokinetic,
             akinetic, or dyskinetic (echocardiography or MRI) 6-No HIV/Viral hepatitis 7-Normal
             liver function (SGPT &lt; 3 times the upper reference range) 8-No or controlled diabetes
             (hemoglobin A1C &lt; 8.5%) 9- Ability to provide informed consent and follow-up with
             protocol procedures

        Exclusion Criteria:

          -  1 prior ICD placement(&lt;2w)/Sustained ventricular arrhythmias 2-Cardiogenic shock 3-
             pregnancy and Child-bearing 4- Congenital / valvular heart disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hamid Gourabi, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Head of Royan Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nasser Aghdami, MD,PhD</last_name>
    <role>Study Director</role>
    <affiliation>Head of Royan department of degenerative medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ahmad Amin, MD</last_name>
    <role>Study Director</role>
    <affiliation>Department of Heart failure,Shahid Rajaee Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Farveh Vakilian, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Heart failure , Imam reza hospital, Mashhad, Iran</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nasser Aghdami, MD,PhD</last_name>
    <phone>+9821235622000</phone>
    <phone_ext>504</phone_ext>
    <email>nasser.aghdami@royaninstitute.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Leila Arab, MD</last_name>
    <phone>+982123562000</phone>
    <phone_ext>414</phone_ext>
    <email>leila.arab@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Royan Institute</name>
      <address>
        <city>Tehran</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nasser Aghdami, MD,PhD</last_name>
      <phone>+982123562000</phone>
      <phone_ext>504</phone_ext>
      <email>nasser.aghdami@royaninstitute.org</email>
    </contact>
    <contact_backup>
      <last_name>Leila Arab, MD</last_name>
      <phone>+982123562000</phone>
      <phone_ext>414</phone_ext>
      <email>leila.arab@yahoo.com</email>
    </contact_backup>
    <investigator>
      <last_name>Hoda Madani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sadaf Vahdat, PhD student</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <link>
    <url>http://Royaninstitute.org</url>
  </link>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 24, 2012</study_first_submitted>
  <study_first_submitted_qc>December 24, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 1, 2013</study_first_posted>
  <last_update_submitted>December 3, 2015</last_update_submitted>
  <last_update_submitted_qc>December 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 4, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cardiac stem ce heart failure cardiac function intracoronary transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

